GT200500063A - Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias - Google Patents

Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias

Info

Publication number
GT200500063A
GT200500063A GT200500063A GT200500063A GT200500063A GT 200500063 A GT200500063 A GT 200500063A GT 200500063 A GT200500063 A GT 200500063A GT 200500063 A GT200500063 A GT 200500063A GT 200500063 A GT200500063 A GT 200500063A
Authority
GT
Guatemala
Prior art keywords
schizophrenia
treatment
glucoregulatory
abnormalities
glucoregulatory abnormalities
Prior art date
Application number
GT200500063A
Other languages
English (en)
Inventor
Craig P Smith
David E Rampe
Borowsky Beth
Kongsamut Sathapana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500063A publication Critical patent/GT200500063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

LA PRESENTE INVENCION SE REFIERE A METODO PARA TRATAR LA ESQUIZOFRENIA EN HUMANOS QUE COMPRENDE ADMINISTRAR UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DEL COMPUESTO DE FORMULA GENERAL I EN LA QUE R,R1,R2,R3,M,N,P, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. T2005
GT200500063A 2004-04-01 2005-03-22 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias GT200500063A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
GT200500063A true GT200500063A (es) 2005-10-14

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500063A GT200500063A (es) 2004-04-01 2005-03-22 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias

Country Status (26)

Country Link
US (1) US20070129403A1 (es)
EP (2) EP2138176A1 (es)
JP (1) JP2007531730A (es)
KR (1) KR20070010161A (es)
CN (1) CN1946399A (es)
AR (1) AR048197A1 (es)
AT (1) ATE446754T1 (es)
AU (1) AU2005231446A1 (es)
BR (1) BRPI0509512A (es)
CA (1) CA2561162A1 (es)
CL (1) CL2009001605A1 (es)
CY (1) CY1109734T1 (es)
DE (1) DE602005017373D1 (es)
DK (1) DK1734959T3 (es)
DO (1) DOP2005000050A (es)
ES (1) ES2334241T3 (es)
GT (1) GT200500063A (es)
IL (1) IL178168A0 (es)
MX (1) MXPA06011222A (es)
PA (1) PA8628601A1 (es)
PL (1) PL1734959T3 (es)
PT (1) PT1734959E (es)
SI (1) SI1734959T1 (es)
SV (1) SV2006002069A (es)
TW (1) TW200602040A (es)
WO (1) WO2005097122A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
BRPI0719210A2 (pt) 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2350090B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
KR20120131162A (ko) 2010-02-26 2012-12-04 제논 파마슈티칼스 인크. 국소 투여용 스피로-옥스인돌 화합물의 약제학적 조성물 및 치료제로서의 이의 용도
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US11862337B2 (en) * 2019-03-19 2024-01-02 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
DK0840609T3 (da) * 1995-07-27 2002-09-30 Aventis Pharma Inc Anvendelse af usubstituerede og substituerede N-(pyrrol-1-yl)pyridinaminer som antikonvulsive midler
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
EP1734959B1 (en) 2009-10-28
DK1734959T3 (da) 2010-03-08
US20070129403A1 (en) 2007-06-07
WO2005097122A2 (en) 2005-10-20
AU2005231446A1 (en) 2005-10-20
CY1109734T1 (el) 2014-09-10
ES2334241T3 (es) 2010-03-08
IL178168A0 (en) 2006-12-31
CN1946399A (zh) 2007-04-11
CL2009001605A1 (es) 2009-11-27
MXPA06011222A (es) 2007-01-16
PL1734959T3 (pl) 2010-03-31
ATE446754T1 (de) 2009-11-15
SV2006002069A (es) 2006-05-24
AR048197A1 (es) 2006-04-05
WO2005097122A3 (en) 2006-02-02
CA2561162A1 (en) 2005-10-20
BRPI0509512A (pt) 2007-09-11
SI1734959T1 (sl) 2010-02-26
EP2138176A1 (en) 2009-12-30
TW200602040A (en) 2006-01-16
EP1734959A2 (en) 2006-12-27
KR20070010161A (ko) 2007-01-22
DE602005017373D1 (de) 2009-12-10
PA8628601A1 (es) 2006-05-16
JP2007531730A (ja) 2007-11-08
PT1734959E (pt) 2009-12-24
DOP2005000050A (es) 2005-11-30

Similar Documents

Publication Publication Date Title
GT200500063A (es) Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
AR060089A1 (es) Tratamiento del dolor
DOP2010000067A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
CU20110142A6 (es) Procedimiento para tratar enfermedades inflamatorias o alérgicas
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
ECSP12011880A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
ECSP056064A (es) Compuestos de benzopirano utiles para tratar estados inflamatorios
ECSP088811A (es) Compuestos orgánicos y sus usos
GT200600475A (es) Derivados de pirazina
ATE523495T1 (de) Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente
CR9782A (es) Composiciones de carbohidratos obtenidas a partir de hongos basidiomicetes para ser utilizadas como agentes biocidas contra patogenos
HK1114876A1 (en) Arthrospira-based compositions and uses thereof
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MX2011008899A (es) Nuevas orto-aminoamidas para el tratamiento del cancer.
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
GT200500308A (es) Nonadepsipeptidos acilados ii